- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00946218
Diagnosis and Characterization of Dengue Fever in Children
October 3, 2011 updated by: St. Jude Children's Research Hospital
Dengue virus is an arbovirus transmitted by mosquitoes which causes significant morbidity and mortality among children in tropical regions, especially in resource limited countries.
The objective of this protocol is to compare the sensitivity and specificity of clinical gestalt and two rapid antigen tests for dengue virus and to compare the gene expression of leukocytes in distinct dengue fever disease phenotypes module-based RNA microarray technology.
Study Overview
Status
Completed
Conditions
Detailed Description
This is a biology protocol with no treatment regimen associated.
Blood collection will be drawn from subjects in El Salvador to be tested in an effort to improve detection and test sensitivity and specificity of a dengue NS1 Ag ELISA, dengue NS1 Ag STRIP, and clinical suspicion for the detection of dengue virus infection in children in San Salvador, El Salvador compared to the gold standard, PCR.
This protocol will also seek to identify and compare gene transcription patterns characteristics of each dengue virus disease phenotype in children.
Study Type
Observational
Enrollment (Actual)
258
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
San Salvador, El Salvador
- Hospital Nacional de Niños Benjamín Bloom
-
-
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 11 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Children subject presenting to Benjamin Bloom Children's Hospital in San Salvador, El Salvador.
Description
Inclusion Criteria Part A:
- Age: Greater than or equal to 6 months and less than 13 years
- One of the following; History of fever OR a history of spontaneous or provoked bleeding
Inclusion Criteria Part B:
- Gender: Female
- Age: greater than or equal to 36 months
- Tanner stage less than 2
- One of the following criteria: Classical Dengue Fever, Dengue Hemorrhagic Fever or Dengue Shock Syndrome
Exclusion Criteria for both parts:
- Obvious alternative explanation for the actual illness
- Cellulitis/Abscess
- Osteomyelitis
- Varicella
- Urinary Tract Infection
- Known immunocompromising condition
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Part A
Children with presumptive dengue infection enrolled for empiric cost modeling with retrospective clinical estimation and comparison of test performance to the standard of care.
|
|
Part B
Children with definitive dengue infection enrolled for gene expression analysis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To compare the sensitivity of dengue NS1 (influenze protein) Ag Enzyme-linked Immunosorbent Assay and dengue NS1 Ag STRIP and WHO clinical diagnostic criteria when applied to children in El Salvador.
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To identify differences in host leukocyte gene expression in children with DF, DHF, and DSS using high throughput gene expression arrays.
Time Frame: 1 Year
|
1 Year
|
|
To develop a clinical risk algorithm for predicting severe dengue using NS1 Ag testing techniques and clinical data.
Time Frame: 1 Year
|
1 Year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2009
Primary Completion (Actual)
December 1, 2009
Study Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
July 22, 2009
First Submitted That Met QC Criteria
July 23, 2009
First Posted (Estimate)
July 24, 2009
Study Record Updates
Last Update Posted (Estimate)
October 5, 2011
Last Update Submitted That Met QC Criteria
October 3, 2011
Last Verified
October 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DENGEN
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dengue Fever
-
Mahidol UniversityRecruitingDengue Fever | Dengue Fever With Warning Signs | Dengue Disease | Dengue Haemorrhagic FeverThailand
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseaseVietnam
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesPeru
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesSingapore
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesMexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic FeverSingapore
-
SanofiCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue VirusUnited States
-
SanofiCompletedDengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue VirusAustralia
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesThailand
-
Sanofi Pasteur, a Sanofi CompanyUnited States Department of DefenseCompletedDengue | Dengue Fever | Dengue Hemorrhagic FeverUnited States